TORONTO, May 10 (Reuters) - Canadian biotechnology company Tekmira Pharmaceuticals said on Monday that Bristol-Myers Squibb will use its gene technology for additional research. Bristol-Myers will pay Vancouver-based Tekmira $3 million to use its gene silencing technology. Tekmira is responsible for providing a number of gene batches over the four-year agreement. Bristol-Myers will have the first right to negotiate a licensing agreement on certain gene products developed by Tekmira. ($1=$1.02 Canadian) (Reporting by Scott Anderson; Editing by Derek Caney) Keywords: TEKMIRA/ (firstname.lastname@example.org; +1 416 941 8106; Reuters Messaging: email@example.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.